Grifols, S.A. (GIKLY)
USD 5.13
(0.0%)
USD 5.13
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.59 Billion EUR | 8.71% |
| 2022 | 6.06 Billion EUR | 22.92% |
| 2021 | 4.93 Billion EUR | -7.62% |
| 2020 | 5.34 Billion EUR | 4.73% |
| 2019 | 5.09 Billion EUR | 13.64% |
| 2018 | 4.48 Billion EUR | 3.91% |
| 2017 | 4.31 Billion EUR | 6.62% |
| 2016 | 4.04 Billion EUR | 2.93% |
| 2015 | 3.93 Billion EUR | 17.26% |
| 2014 | 3.35 Billion EUR | 22.38% |
| 2013 | 2.74 Billion EUR | 4.61% |
| 2012 | 2.62 Billion EUR | 45.96% |
| 2011 | 1.79 Billion EUR | 81.24% |
| 2010 | 990.73 Million EUR | 8.49% |
| 2009 | 913.18 Million EUR | 12.14% |
| 2008 | 814.31 Million EUR | 15.79% |
| 2007 | 703.29 Million EUR | 8.4% |
| 2006 | 648.79 Million EUR | 23.75% |
| 2005 | 524.27 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.62 Billion EUR | -8.13% |
| 2024 Q2 | 1.81 Billion EUR | 11.82% |
| 2023 Q2 | 1.66 Billion EUR | 7.83% |
| 2023 Q3 | 1.59 Billion EUR | -3.97% |
| 2023 FY | 6.59 Billion EUR | 8.71% |
| 2023 Q1 | 1.54 Billion EUR | -9.93% |
| 2023 Q4 | 1.76 Billion EUR | 10.77% |
| 2022 Q1 | 1.26 Billion EUR | 5.75% |
| 2022 FY | 6.06 Billion EUR | 22.92% |
| 2022 Q4 | 1.71 Billion USD | 11.14% |
| 2022 Q3 | 1.54 Billion EUR | -0.11% |
| 2022 Q2 | 1.54 Billion EUR | 21.76% |
| 2021 Q1 | 1.18 Billion EUR | -9.52% |
| 2021 Q3 | 1.19 Billion EUR | -11.37% |
| 2021 Q2 | 1.35 Billion EUR | 14.11% |
| 2021 FY | 4.93 Billion EUR | -7.62% |
| 2021 Q4 | 1.19 Billion USD | 0.0% |
| 2020 Q3 | 1.35 Billion EUR | -2.21% |
| 2020 FY | 5.34 Billion EUR | 4.73% |
| 2020 Q1 | 1.29 Billion EUR | -4.97% |
| 2020 Q2 | 1.38 Billion EUR | 7.01% |
| 2020 Q4 | 1.3 Billion EUR | -3.25% |
| 2019 Q2 | 1.26 Billion EUR | 9.49% |
| 2019 Q4 | 1.36 Billion EUR | 3.54% |
| 2019 FY | 5.09 Billion EUR | 13.64% |
| 2019 Q1 | 1.15 Billion EUR | -5.4% |
| 2019 Q3 | 1.31 Billion EUR | 3.78% |
| 2018 Q2 | 1.09 Billion EUR | 7.24% |
| 2018 Q1 | 1.02 Billion EUR | -4.2% |
| 2018 FY | 4.48 Billion EUR | 3.91% |
| 2018 Q3 | 1.14 Billion EUR | 4.26% |
| 2018 Q4 | 1.22 Billion EUR | 6.91% |
| 2017 FY | 4.31 Billion EUR | 6.62% |
| 2017 Q4 | 1.06 Billion EUR | 0.96% |
| 2017 Q3 | 1.05 Billion EUR | -6.46% |
| 2017 Q2 | 1.13 Billion EUR | 6.51% |
| 2017 Q1 | 1.06 Billion EUR | -3.32% |
| 2016 Q1 | 958.93 Million EUR | -9.77% |
| 2016 Q2 | 992.71 Million EUR | 3.52% |
| 2016 Q3 | 1 Billion EUR | 0.74% |
| 2016 FY | 4.04 Billion EUR | 2.93% |
| 2016 Q4 | 1.09 Billion EUR | 9.81% |
| 2015 Q3 | 971.19 Million EUR | -2.11% |
| 2015 Q1 | 908.38 Million EUR | -0.97% |
| 2015 FY | 3.93 Billion EUR | 17.26% |
| 2015 Q2 | 992.18 Million EUR | 9.22% |
| 2015 Q4 | 1.06 Billion EUR | 9.43% |
| 2014 Q4 | 917.29 Million EUR | 10.88% |
| 2014 FY | 3.35 Billion EUR | 22.38% |
| 2014 Q3 | 827.31 Million EUR | 1.79% |
| 2014 Q2 | 812.78 Million EUR | 1.85% |
| 2014 Q1 | 797.99 Million EUR | 14.79% |
| 2013 Q4 | 695.16 Million EUR | 4.42% |
| 2013 FY | 2.74 Billion EUR | 4.61% |
| 2013 Q1 | 683.69 Million EUR | 3.37% |
| 2013 Q2 | 697.14 Million EUR | 1.97% |
| 2013 Q3 | 665.72 Million EUR | -4.51% |
| 2012 Q3 | 642.81 Million EUR | -1.11% |
| 2012 Q2 | 650.02 Million EUR | -2.5% |
| 2012 Q1 | 666.68 Million EUR | 12.98% |
| 2012 FY | 2.62 Billion EUR | 45.96% |
| 2012 Q4 | 661.42 Million EUR | 2.9% |
| 2011 Q3 | 570.19 Million EUR | 52.5% |
| 2011 Q4 | 590.07 Million EUR | 3.49% |
| 2011 FY | 1.79 Billion EUR | 81.24% |
| 2011 Q1 | 261.43 Million EUR | 3.78% |
| 2011 Q2 | 373.9 Million EUR | 43.02% |
| 2010 FY | 990.73 Million EUR | 8.49% |
| 2010 Q4 | 251.9 Million EUR | 30.44% |
| 2010 Q3 | 193.12 Million EUR | 0.0% |
| 2009 FY | 913.18 Million EUR | 12.14% |
| 2008 FY | 814.31 Million EUR | 15.79% |
| 2007 FY | 703.29 Million EUR | 8.4% |
| 2006 FY | 648.79 Million EUR | 23.75% |
| 2005 FY | 524.27 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | 85.949% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 85.353% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 79.04% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -47130.615% |
| Novartis AG | 46.66 Billion USD | 85.872% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | -233.064% |